MA-PERKINELMER
17.3.2021 17:05:11 CET | Business Wire | Press release
PerkinElmer , Inc., a global leader committed to innovating for a healthier world, today announced its industry-leading documentation, workflow and decision making Signals™ informatics platform is being expanded to build on existing capabilities in the biologics drug discovery space. This comes through a collaboration with Insightful Science , a software company serving the global life sciences community.
With the collaboration, pharmaceutical and academic research teams can bring together the power of the PerkinElmer Signals™ platform with leading solutions from Insightful Science’s Bioinformatics division. This includes the popular SnapGene and Geneious Prime software offerings that help molecular biologists design and execute DNA construct design, molecular cloning and other kinds of molecular biology research. The integration will give scientists the ability to access and compare data across experiments and instruments and collaborate more intuitively. They can also replicate assays and experiments instantly, leading to faster time-to-result and more informed decision making on drug and vaccine targets.
“There is a limited availability of IT tools in the biologics space,” said Kevin Willoe, VP and GM of PerkinElmer, Informatics. “Through our collaboration with Insightful Science, we’re able to provide enhanced informatics capabilities to scientists doing vital biologics and vaccine research. This will help significantly reduce cycle times for researchers and aid them in making data-driven decisions faster and more accurately - important capabilities when fighting foes like cancer, cardio, neurological and viral diseases.”
"The integration of best-in-class scientific software with cloud-based data platforms is increasingly essential for modern pharmaceutical and biotech enterprises to streamline research and ensure the integrity of valuable data,” added Brett Ammundsen, CEO Bioinformatics at Insightful Science. “The combination of SnapGene and Geneious Prime software with the PerkinElmer Signals platform powerfully enhances research workflows and enriches collaboration. Ultimately this will better connect scientists to their ideas and data, so they can focus on producing life-changing outcomes.”
For more information about the PerkinElmer Signals™ platform, click here . To learn more about Insightful Science, including the Geneious Prime and SnapGene software offerings, visit www.insightfulscience.com .
About PerkinElmer
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com
About Insightful Science
Insightful Science is a life sciences software company that digitally connects researchers to their ideas and data, advancing the discovery process. From developing new personalized and preventive patient treatment solutions to reversing climate change — more than 2 million researchers at leading life science and biopharma enterprises trust Insightful Science products to make the world a healthier, cleaner, and better place to live. Products within the Insightful Science portfolio were built by prominent scientists, and include GraphPad Prism, Geneious Prime and Geneious Biologics, SnapGene, nQuery, Cytapex, and more. Visit www.insightfulscience.com for more information about the company and its products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005650/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H55 Delivers Certification-Grade Propulsion Battery Modules to Pratt & Whitney Canada, Supporting Demonstration of Hybrid-Electric Aircraft Technology9.6.2026 17:31:00 CEST | Press release
Production-conforming systems manufactured in a regulator-approved facility mark H55’s transition from technology development to commercialization of certification-grade energy storage solutions for hybrid-electric aviation. H55 today announced the delivery of certification-grade propulsion battery modules to Pratt & Whitney Canada in support of the RTX Hybrid-Electric Flight Demonstrator — a milestone that further validates H55’s transition from technology development to industrial-scale execution and represents an important step in the commercialization of the company’s certification-grade energy storage technologies for hybrid-electric aerospace applications. Pratt & Whitney is an RTX business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609825006/en/ H55 Adagio Battery Modules in Pratt & Whitney Canada Hangar ©RTX The delivery represents more than hardware integration. It demonstrates H55’s ability to manufacture p
New Polymorph of Indomethacin Discovered9.6.2026 17:00:00 CEST | Press release
- Joint Research Involving Rigaku Published in Crystal Growth & Design - Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced that the results of a joint research project conducted with Shionogi & Co., Ltd., JEOL Ltd., and Meiji Pharmaceutical University have been published in Crystal Growth & Design, a world-renowned international journal in the field of crystallography. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609347405/en/ Cover of the June 2026 issue of Crystal Growth & Design, featuring this research. This research uncovered a previously unknown polymorph (κ-form) of indomethacin, a widely used pain relief and anti-inflammatory drug. The research team also conducted structural analysis and characterization of the newly identified crystal form. Although indomethacin has
SLB Collaborates with Qualcomm on Edge AI Solutions for Energy Operations9.6.2026 16:28:00 CEST | Press release
Collaboration combines edge computing and energy workflows to support real-time operational decision-making Global energy technology company SLB (NYSE: SLB) today announced a memorandum of understanding with Qualcomm Technologies, Inc. to enable edge AI solutions for the energy industry, supporting real-time operational decision-making across wells, facilities and production systems. The collaboration combines Qualcomm Technologies’ low-power edge computing and AI processing capabilities, with SLB’s Agora™ edge AI and IoT solutions developed for remote and operationally complex environments. “Together, SLB and Qualcomm Technologies aim to help operators apply AI more effectively across energy infrastructure,” said Rakesh Jaggi, president, Digital, SLB. “Many energy operations rely on real-time decision-making in remote environments where connectivity and responsiveness directly affect performance. AI systems designed around the realities of energy operations can help support more consi
RevBits and Stony Brook University’s Ethos Lab Establish a Collaborative Partnership to Further the Field of Cyber Security Education and Application9.6.2026 16:15:00 CEST | Press release
Through the partnership, RevBits will provide its full suite of cybersecurity solutions to Stony Brook University’s Ethos Lab, to deliver the capability to advance student education and equip them with the knowledge needed to face modern cyber threats in a realistic, contained environment. Stony Brook University’s (SBU) Ethos Lab, in the College of Engineering and Applied Sciences Department of Computer Science, recently announced a collaborative partnership with RevBits, LLC. Through the partnership, SBU’s Ethos Lab will utilize the RevBits solutions suite to build computer science labs and a cybersecurity-focused curriculum, reinforcing lessons from the classroom. The platform simulates environments containing five major threat landscapes, including Endpoint Security, Privileged Access Management, Email Security, Zero Trust Network and Deception Technology. SBU’s Department of Computer Science was recently designated as a National Center of Academic Excellence in Cybersecurity Resear
Marie® by Leo Cancer Care Makes History at Stanford Medicine — World First in Compact Upright Proton Therapy9.6.2026 15:22:00 CEST | Press release
The first patient treated was a child. The milestone marks the moment upright proton therapy moves from innovation to adoption — and reflects exactly what Leo Cancer Care built Marie® to achieve Following the landmark first treatment at Stanford Medicine Cancer Center Care June 4, Leo Cancer Care today announces the role of its Marie® upright patient positioning and imaging platform in enabling the world's first compact upright proton therapy patient treatment. Delivered using the Mevion S250-FIT™ Proton Therapy System and powered by RayStation from RaySearch, the milestone is the culmination of a decade of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609870736/en/ The treatment room at Stanford Medicine Cancer Center, Palo Alto, California, housing the Marie® upright patient positioning platform by Leo Cancer Care (center foreground) integrated with the Mevion S250-FIT™ Proton Therapy System. The circular
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom